Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc boosted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 81.0% in the 3rd quarter, Holdings Channel reports. The firm owned 470,603 shares of the company’s stock after buying an additional 210,576 shares during the period. Impax Asset Management Group plc’s holdings in Pacira BioSciences were worth $7,083,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Texas Permanent School Fund Corp lifted its stake in Pacira BioSciences by 1.4% during the first quarter. Texas Permanent School Fund Corp now owns 40,642 shares of the company’s stock valued at $1,188,000 after purchasing an additional 543 shares during the last quarter. Inspire Investing LLC lifted its stake in Pacira BioSciences by 5.9% during the first quarter. Inspire Investing LLC now owns 12,131 shares of the company’s stock valued at $354,000 after purchasing an additional 675 shares during the last quarter. ProShare Advisors LLC lifted its stake in Pacira BioSciences by 8.0% during the first quarter. ProShare Advisors LLC now owns 12,461 shares of the company’s stock valued at $364,000 after purchasing an additional 924 shares during the last quarter. GAMMA Investing LLC lifted its stake in Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after purchasing an additional 932 shares during the last quarter. Finally, Outfitter Financial LLC lifted its stake in Pacira BioSciences by 5.7% during the second quarter. Outfitter Financial LLC now owns 20,190 shares of the company’s stock valued at $578,000 after purchasing an additional 1,095 shares during the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on PCRX. StockNews.com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. Raymond James downgraded shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. restated an “underweight” rating and issued a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Barclays reduced their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday. Finally, Truist Financial downgraded shares of Pacira BioSciences from a “buy” rating to a “sell” rating and reduced their price target for the company from $30.00 to $8.00 in a research report on Tuesday, August 13th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $23.50.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $16.60 on Friday. The company’s fifty day moving average is $15.75 and its 200-day moving average is $20.74. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The firm has a market cap of $766.42 million, a price-to-earnings ratio of -8.18 and a beta of 0.82. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.